DNB Markets analyst Geir Hiller Holom downgraded BerGenBio to Sell from Hold with a price target of NOK 1, down from NOK 9. The analyst sees the terms of the rights issue financing as "detrimental to the stock" and also struggles to identify substantial share price catalysts for the next 12- 18 months.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on BRRGF: